Overview

Study Of ATRN-119 In Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Atrin Pharmaceuticals